Motivista, the prescription digital therapeutic developed as CT-155, is US-cleared for negative symptoms of schizophrenia as an addition to clinician-managed outpatient care, including antipsychotic therapy. Its pivotal trial found an improvement on a motivation-and-pleasure measure. That is a more specific finding than a general claim that an app improves every aspect of schizophrenia.
The distinction matters both for understanding the trial and for identifying the people covered by the indication.
The current indication and the research name
The FDA’s July decision and public summary describe adults aged 18 and over with clinically stable positive symptoms. Positive symptoms, such as hallucinations and delusions, are distinct from the negative-symptom difficulties the app is intended to address.
The indication retains clinician-managed care and antipsychotic therapy. It does not describe an app replacing medication or independently managing an acute episode.
The published CONVOKE trial uses CT-155 and investigational terminology to describe the research. The FDA decision records clearance on 30 July 2026 under the Motivista name. Historical wording in a study or older product description should therefore not be mistaken for the current regulatory status.
The manufacturer’s product information identifies the same programme. Clearance establishes a defined marketing authorisation; it does not by itself establish local prescribing arrangements, reimbursement or availability for every interested person.
What the digital intervention asked people to do
The app combined structured goal setting with cognitive and behavioural techniques. The approach sought to help participants engage in rewarding activities and address beliefs that could undermine attempts to do so.
CONVOKE compared it with a digital control providing disease-related educational material. Both were added to existing pharmacological care. This was not a comparison between receiving an app and receiving no care.
That design is relevant to interpreting engagement. Time spent in an app is a process measure, while a change in symptoms is an outcome. More screen time cannot be assumed to be the mechanism of a therapeutic benefit simply because both are recorded.
Which symptoms changed
The trial randomised 457 unique participants: 227 to CT-155 and 230 to the digital control. At sixteen weeks, the modelled difference in change on the Clinical Assessment Interview for Negative Symptoms’ motivation-and-pleasure measure favoured CT-155 by 2.6 points. The reported 95% confidence interval ran from 1.2 to 4.0 points in its favour.
The expression-related negative-symptom measure and the positive-symptom measure did not show the same established between-group improvement. Those findings help define the result; they are not details to omit from a broad symptom claim.
The analysis also used a repeated-measures model with missing follow-up observations. The number randomised, the number contributing assessments and the number observed at a particular visit are consequently different denominators. The headline result should not be described as if every participant supplied a complete sixteen-week measurement.
Who was represented, and what remains open
Participants needed stable antipsychotic treatment, smartphone and internet access, and circumstances allowing participation in the study. Some clinical presentations and recent psychological treatments were excluded. These requirements limit how confidently the findings can be carried into less supported settings or different stages of illness.
The paper and FDA submission describe a separate safety population that includes people exposed to an app. It is larger than the unique randomised population, and should not be added to it. Serious events were assessed within the study; reported tolerability does not establish the absence of rare risks in wider use.
The work was sponsored by the developers, with company involvement disclosed in the paper. Sixteen-week findings also leave questions about durability, everyday use and longer-term functioning.
The useful conclusion is therefore specific: a defined digital intervention added to ongoing care improved the trial’s motivation-and-pleasure outcome in the studied adults. The current indication, the comparator and the symptoms that did not show the same difference belong beside that finding.